Nrf2 Induction Re-establishes a Proper Neuronal Differentiation Program in Friedreich’s Ataxia Neural Stem Cells-Reference-Cited by-同舟云学术

Nrf2 Induction Re-establishes a Proper Neuronal Differentiation Program in Friedreich’s Ataxia Neural Stem Cells

Published:2019-07-31 Issue: Volume:13 Page:
ISSN:1662-5102
Container-title:Frontiers in Cellular Neuroscience
language:
Short-container-title:Front. Cell. Neurosci.

Author:

La Rosa Piergiorgio,Russo Marta,D’Amico Jessica,Petrillo Sara,Aquilano Katia,Lettieri-Barbato Daniele,Turchi Riccardo,Bertini Enrico S.,Piemonte Fiorella

Publisher

Frontiers Media SA

Subject

Cellular and Molecular Neuroscience

Reference71 articles.

1. Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in friedreich’s ataxia models.;Abeti;Front. Cell. Neurosci.,2018

2. Molecular alterations in a mouse cardiac model of friedreich ataxia: an impaired Nrf2 response mediated via upregulation of keap1 and activation of the Gsk3β axis.;Anzovino;Am. J. Pathol.,2017

3. An internet-accessible database of mouse developmental anatomy based on a systematic nomenclature.;Bard;Mech. Dev.,1998

4. Nrf2, cellular redox regulation, and neurologic implications.;Benarroch;Neurology,2017

5. Friedreich ataxia: current status and future prospects.;Bürk;Cerebellum Ataxias,2017

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SIRT1-driven mechanism: sevoflurane’s interference with mESC neural differentiation via PRRX1/DRD2 cascade;Human Molecular Genetics;2024-08-01

2. Recent Advances in the Treatment Strategies of Friedreich’s Ataxia: A Review of Potential Drug Candidates and their Underlying Mechanisms;Current Pharmaceutical Design;2024-05

3. Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available data;Expert Opinion on Pharmacotherapy;2024-03-23

4. Roles of Glutathione and AP-1 in the Enhancement of Vitamin D-Induced Differentiation by Activators of the Nrf2 Signaling Pathway in Acute Myeloid Leukemia Cells;International Journal of Molecular Sciences;2024-02-14

5. Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia;Trends in Molecular Medicine;2024-02